Twist Bioscience Corp (TWST): Cash & Equivalents
$183.05M
As of 2025-09-30
$117.44M
As of 2026-06-30
-21.5%
3-year compound annual growth
+14.3%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $183.05M | -19.1% | 2025-11-17, Balance as of period end |
| 2024-09-30 | $226.32M | -21.0% | 2025-11-17, Balance as of period end |
| 2023-09-30 | $286.47M | -24.4% | 2024-11-18, Balance as of period end |
| 2022-09-30 | $378.69M | -18.7% | 2023-11-21, Balance as of period end |
| 2021-09-30 | $465.83M | +397.3% | 2023-06-05, Balance as of period end |
| 2020-09-30 | $93.67M | +100.4% | 2021-11-23, Balance as of period end |
| 2019-09-30 | $46.73M | -42.1% | 2020-11-27, Balance as of period end |
| 2018-09-30 | $80.76M | +158.6% | 2020-11-27, Balance as of period end |
| 2017-09-30 | $31.23M | n/a | 2019-12-13, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | 2025-09-30 | $183.05M | -19.1% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $496.30M | +43.9% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $467.71M | +2.6% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $183.64M | +93.7% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $87.63M | -15.0% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $70.50M | +47.1% |
| Vericel Corp (VCEL) | 2025-12-31 | $100.09M | +34.3% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $163.08M | +41.0% |
| Repligen Corp (RGEN) | 2025-12-31 | $566.02M | -25.3% |
Compare TWST, KRYS, IMCR, TARS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗